Highly-effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator
therapy (HEMT) corrects the underlying molecular defect causing cystic fibrosis (CF) …

The arrival of cystic fibrosis transmembrane conductance regulator (CFTR) modulators as a
new class of treatment for cystic fibrosis (CF) in 2012 represented a pivotal advance in …

Background Cystic fibrosis (CF) lung transplant (LT) recipients may warrant treatment with
elexacaftor/tezacaftor/ivacaftor (ETI) to improve extrapulmonary manifestations of CF. Our …

Cystic fibrosis (CF) pathophysiology is hallmarked by excessive inflammation and the
inability to efficiently resolve lung infections, contributing to morbidly and eventually the …

Cystic fibrosis in characterized by pulmonary bacterial colonization and hyperinflammation.
Lymphocytes, monocytes/macrophages, neutrophils, and dendritic cells of patients with CF …

Background CFTR modulators decrease some etiologies of CF airway inflammation;
however, data indicate that non-resolving airway infection and inflammation persist in …

Cystic fibrosis (CF) is caused by a defect in the cystic fibrosis transmembrane conductance
regulator protein (CFTR) which instigates a myriad of respiratory complications including …

Acquired cystic fibrosis transmembrane regulator (CFTR) dysfunctions have been
associated with several conditions, including myocardial infarction (MI). Here, CFTR is …

Glioblastoma (GBM) is the most common and malignant primary brain tumor. Glioblastoma
stem cells (GSCs) not only initiate and sustain uncontrolled cell proliferation but also …

communities with associated opportunities for developing novel antimicrobial therapies,
evolving knowledge regarding the surveillance and management of long-term endocrine …